)
Visual
test
Acumen Pharmaceuticals
Acumen Pharmaceuticals (ABOS) investor relations material
Acumen Pharmaceuticals Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary26 Mar, 2026
Company overview and business model
Clinical-stage biopharmaceutical company focused on disease-modifying therapies for Alzheimer's disease, targeting amyloid-beta oligomers (AßOs) as a primary cause of pathology.
Lead candidate sabirnetug is in Phase 2 ALTITUDE-AD trial, with topline results expected in late 2026; also developing subcutaneous and enhanced brain delivery (EBD) formulations.
Collaboration with JCR Pharmaceuticals to develop AßO-targeted EBD therapies, with potential milestone and royalty payments.
Financial performance and metrics
Gross proceeds from the March 2026 private placement were approximately $35.75 million, before fees and expenses.
Financial statements audited by Ernst & Young LLP, with a going concern explanatory paragraph included.
Use of proceeds and capital allocation
No proceeds from the resale of shares by selling stockholders; all registration expenses borne by the company, while selling stockholders bear their own selling costs.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Acumen Pharmaceuticals
- ALTITUDE-AD phase II and EBD advances fueled by $35.75M placement and $116.9M cash reserves.ABOS
Q4 202526 Mar 2026 - Phase II Alzheimer's trial for sabirnetug targets late 2026 data, with EBD clinical entry by 2027.ABOSStifel 2026 Virtual CNS Forum18 Mar 2026
- Sabirnetug targets toxic amyloid beta oligomers, showing strong early efficacy and safety data.ABOSCorporate presentation18 Mar 2026
- Phase 2 enrollment and R&D spending rise; $281.4M cash supports runway into 2027.ABOSQ2 20241 Feb 2026
- Sabirnetug shows strong target engagement, safety, and rapid phase II trial enrollment.ABOSH.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026
- Phase II and subcutaneous studies advance, with strong data and cash runway into 1H 2027.ABOSR&D Day 202420 Jan 2026
- Sabirnetug aims to improve Alzheimer's outcomes by targeting Aβ oligomers, with pivotal trials underway.ABOSBank of America CNS Therapeutics Virtual Conference19 Jan 2026
- Pivotal Alzheimer's trials advance; $259M cash supports operations into H1 2027.ABOSQ3 202415 Jan 2026
- Rapid clinical progress and strategic advances position the program for pivotal milestones by 2026.ABOSUBS Global Healthcare Conference 202414 Jan 2026
Next Acumen Pharmaceuticals earnings date
Q1 202612 May, 2026
Acumen Pharmaceuticals
Next Acumen Pharmaceuticals earnings date
Q1 202612 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage